drugset / Trial / NCT03979742

Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training

NCT03979742

Phase 2 Terminated 6 enrolled StemCyte, Inc. StemCyte Taiwan Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Umbilical cord blood mononuclear stem cells (UCBMSCs) transplant followed by the intensive locomotor training for up to 5±1 hours a day, 5±1 days a week, and for 3-6 months for treatment in patients with chronic, stable and complete spinal cord injury.

Timeline

Start
2022-02-22
Primary completion
2024-12-30
Completion
2024-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Umbilical Cord Blood Mononuclear Cell Cell therapy 6.4e+06 cells Other

Indications